Association of Reduced Hospitalizations and Mortality Rates Among COVID-19-Vaccinated Patients With Heart Failure

Johnson, Kipp W.; Patel, Sonika; Thapi, Sahityasri; Jaladanki, Suraj; Rao, Aarti K.; Nirenberg, Sharon

doi:10.1016/j.cardfail.2022.05.008

Cited by 11 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 108 Unfortunately, the study was terminated prematurely due to the COVID-19 pandemic, but an observational study on >7000 patients with HF showed that COVID-19 vaccination was associated with a substantial reduction in all-cause hospitalization rates and mortality, irrespective of LVEF. 177 RCTs are ongoing in patients with recent MI or HF. 178 …”

Section: Inflammation As a Therapeutic Target In Clinical Trials Of H...mentioning

confidence: 99%

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Pugliese

Pellicori

Filidei

et al. 2022

Cardiovascular Research

View full text Add to dashboard Cite

Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome mainly affecting older people who have many other cardiac and non-cardiac conditions that often cast doubt on the origin of symptoms, such as breathlessness, or signs, such as peripheral oedema, rendering them neither sensitive nor specific to the diagnosis of HFpEF. Currently, management of HFpEF is mainly directed at controlling symptoms and treating comorbid conditions such as hypertension, atrial fibrillation, anaemia and coronary artery disease. HFpEF is also characterised by a persistent increase in inflammatory biomarkers. Inflammation may be a key driver of the development and progression of HFpEF and many of its associated comorbidities. Detailed characterisation of specific inflammatory pathways may provide insights into the pathophysiology of HFpEF and guide its future management. There is growing interest in novel therapies specifically designed to target deregulated inflammation in many therapeutic areas, including cardiovascular disease. However, large-scale clinical trials investigating the effectiveness of anti-inflammatory treatments in HFpEF are still lacking. In this manuscript, we review the role of inflammation in HFpEF and the possible implications for future trials.

show abstract

Section: Inflammation As a Therapeutic Target In Clinical Trials Of H...mentioning

confidence: 99%

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Pugliese

Pellicori

Filidei

et al. 2022

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…Vaccinations against COVID-19 in patients with heart failure are recommended by the major cardiology societies from the USA and Europe [ 43 , 44 ] as they can help reduce morbidity and mortality in this vulnerable population. Jonson et al, in a study consisting of 7094 patients with heart failure, noted a lower likelihood of all-cause hospitalization and mortality in a graded fashion with lower hospitalization and mortality rates in vaccine-boosted individuals and worst in unvaccinated individuals [ 45 ]. Future research should include vaccination’s role in influencing outcomes in patients with COVID-19 infection and heart failure.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and Heart Failure with Preserved and Reduced Ejection Fraction Clinical Outcomes among Hospitalized Patients in the United States

Nasrullah

Gangu

Cannon

et al. 2023

Viruses

View full text Add to dashboard Cite

Heart failure exacerbations impart significant morbidity and mortality, however, large- scale studies assessing outcomes in the setting of concurrent coronavirus disease-19 (COVID-19) are limited. We utilized National Inpatient Sample (NIS) database to compare clinical outcomes in patients admitted with acute congestive heart failure exacerbation (CHF) with and without COVID-19 infection. A total of 2,101,980 patients (Acute CHF without COVID-19 (n = 2,026,765 (96.4%) and acute CHF with COVID-19 (n = 75,215, 3.6%)) were identified. Multivariate logistic regression analysis was utilized to compared outcomes and were adjusted for age, sex, race, income level, insurance status, discharge quarter, Elixhauser co-morbidities, hospital location, teaching status and bed size. Patients with acute CHF and COVID-19 had higher in-hospital mortality compared to patients with acute CHF alone (25.78% vs. 5.47%, adjust OR (aOR) 6.3 (95% CI 6.05–6.62, p < 0.001)) and higher rates of vasopressor use (4.87% vs. 2.54%, aOR 2.06 (95% CI 1.86–2.27, p < 0.001), mechanical ventilation (31.26% vs. 17.14%, aOR 2.3 (95% CI 2.25–2.44, p < 0.001)), sudden cardiac arrest (5.73% vs. 2.88%, aOR 1.95 (95% CI 1.79–2.12, p < 0.001)), and acute kidney injury requiring hemodialysis (5.56% vs. 2.94%, aOR 1.92 (95% CI 1.77–2.09, p < 0.001)). Moreover, patients with heart failure with reduced ejection fraction had higher rates of in-hospital mortality (26.87% vs. 24.5%, adjusted OR 1.26 (95% CI 1.16–1.36, p < 0.001)) with increased incidence of vasopressor use, sudden cardiac arrest, and cardiogenic shock as compared to patients with heart failure with preserved ejection fraction. Furthermore, elderly patients and patients with African-American and Hispanic descents had higher in-hospital mortality. Acute CHF with COVID-19 is associated with higher in-hospital mortality, vasopressor use, mechanical ventilation, and end organ dysfunction such as kidney failure and cardiac arrest.

show abstract

“…Cohort studies have shown reduced cardiovascular complications in patients vaccinated against COVID-19 when compared with those who are unvaccinated, 16 including those with pre-existing cardiac disease. 17 Box 1 summarises the evidence that associates respiratory viruses with cardiovascular deaths, some of which is temporal association but paints a strong picture when considered in total.…”

Section: Levels Of Evidencementioning

confidence: 99%

“…• Reduce cigarette smoking • Patients with COVID-19 have higher rates of cardiovascular deaths in the subsequent months post recovery, even if only affected by a case of COVID-19 that does not require hospitalisation, 1,2 with vaccination offering some protection. 16,17 • In Australia, we managed to substantially reduce cardiovascular deaths in 2020-21 at the same time as we supressed respiratory deaths. 11,12 The rate of cardiovascular deaths has returned to expected levels in early 2022.…”

Section: Emerging Public Health Interventions To Potentially Reduce C...mentioning

confidence: 99%

Prevention of the spread of respiratory viruses such as SARS-CoV-2 can also prevent cardiovascular deaths

Orchard¹,

Orchard

Workman³

et al. 2022

Aust J Gen Pract

View full text Add to dashboard Cite

Association of Reduced Hospitalizations and Mortality Rates Among COVID-19-Vaccinated Patients With Heart Failure

Cited by 11 publications

References 9 publications

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

COVID-19 and Heart Failure with Preserved and Reduced Ejection Fraction Clinical Outcomes among Hospitalized Patients in the United States

Prevention of the spread of respiratory viruses such as SARS-CoV-2 can also prevent cardiovascular deaths

Contact Info

Product

Resources

About